| Literature DB >> 33910814 |
Despoina Spyropoulou1, Panagiotis Tsiganos2, Foteinos-Ioannis Dimitrakopoulos3,4, Maria Tolia5, Angelos Koutras3, Dimitris Velissaris6, Maria Lagadinou7, Nikolaos Papathanasiou8, Areti Gkantaifi9, Haralabos Kalofonos3, Dimitrios Kardamakis10.
Abstract
Renal cell carcinoma (RCC) is one of the most aggressive malignancies of the genito-urinary tract, having a poor prognosis especially in patients with metastasis. Surgical resection remains the gold standard for localized renal cancer disease, with radiotherapy (RT) receiving much skepticism during the last decades. However, many studies have evaluated the role of RT, and although renal cancer is traditionally considered radio-resistant, technological advances in the RT field with regards to modern linear accelerators, as well as advanced RT techniques have resulted in breakthrough therapeutic outcomes. Additionally, the combination of RT with immune checkpoint inhibitors and targeted agents may maximize the clinical benefit. This review article focuses on the role of RT in the therapeutic management of renal cell carcinoma. CopyrightEntities:
Keywords: Renal cell cancer; oligometastatic disease; radioresistance; radiosensitivity; radiotherapy; review; stereotactic body radiation therapy
Mesh：
Year: 2021 PMID： 33910814 PMCID： PMC8193295 DOI： 10.21873/invivo.12389
Source DB: PubMed Journal: In Vivo ISSN： 0258-851X Impact factor: 2.406